Zylox-Tonbridge Medical Technology Co., Ltd.
HKEX:2190.HK
11.96 (HKD) • At close September 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 148.812 | 148.812 | 115.066 | 115.066 | 90.674 | 90.674 | 76.372 | 76.372 | 53.214 | 53.214 | 35.742 | 35.742 | 12.762 | 12.762 | 1.054 | 1.054 |
| Cost of Revenue
| 41.641 | 41.641 | 29.743 | 29.743 | 22.078 | 22.078 | 18.633 | 18.633 | 13.336 | 13.336 | 9.68 | 9.68 | 4.908 | 4.908 | 0.765 | 0.765 |
| Gross Profit
| 107.171 | 107.171 | 85.323 | 85.323 | 68.596 | 68.596 | 57.739 | 57.739 | 39.879 | 39.879 | 26.062 | 26.062 | 7.854 | 7.854 | 0.29 | 0.29 |
| Gross Profit Ratio
| 0.72 | 0.72 | 0.742 | 0.742 | 0.757 | 0.757 | 0.756 | 0.756 | 0.749 | 0.749 | 0.729 | 0.729 | 0.615 | 0.615 | 0.275 | 0.275 |
| Reseach & Development Expenses
| 65.104 | 65.104 | 65.403 | 65.403 | 69.711 | 69.711 | 47.02 | 47.02 | 59.561 | 59.561 | 24.49 | 24.49 | 22.305 | 22.305 | 13.728 | 13.728 |
| General & Administrative Expenses
| 31.865 | 31.865 | 25.179 | 25.179 | 30.027 | 30.027 | 24.642 | 24.642 | 23.218 | 23.218 | 27.082 | 27.082 | 11.918 | 11.918 | 3.579 | 3.579 |
| Selling & Marketing Expenses
| 44.444 | 44.444 | 37.47 | 37.47 | 43.403 | 43.403 | 26.666 | 26.666 | 34.761 | 34.761 | 12.874 | 12.874 | 7.788 | 7.788 | 2.439 | 2.439 |
| SG&A
| 76.317 | 76.317 | 62.649 | 62.649 | 73.442 | 73.442 | 51.308 | 51.308 | 57.989 | 57.989 | 39.956 | 39.956 | 19.705 | 19.705 | 6.018 | 6.018 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 148.366 | 148.366 | 122.39 | 122.39 | 142.107 | 142.107 | 88.427 | 88.427 | 110.16 | 110.16 | 62.019 | 62.019 | 40.719 | 40.719 | 17.506 | 17.506 |
| Operating Income
| -32.514 | -32.514 | -41.066 | -41.066 | -72.962 | -72.962 | -38.794 | -38.794 | -70.928 | -70.928 | -38.155 | -38.155 | -30.998 | -30.998 | -17.673 | -17.673 |
| Operating Income Ratio
| -0.218 | -0.218 | -0.357 | -0.357 | -0.805 | -0.805 | -0.508 | -0.508 | -1.333 | -1.333 | -1.068 | -1.068 | -2.429 | -2.429 | -16.767 | -16.767 |
| Total Other Income Expenses Net
| 10.758 | 10.758 | 23.454 | 23.454 | 28.937 | 28.937 | 26.042 | 26.042 | 5.942 | 5.942 | 3.297 | 3.297 | -1.836 | -1.836 | 0.273 | 0.273 |
| Income Before Tax
| -21.756 | -21.756 | -17.612 | -17.612 | -44.026 | -44.026 | -12.752 | -12.752 | -64.986 | -64.986 | -34.859 | -34.859 | -32.834 | -32.834 | -17.4 | -17.4 |
| Income Before Tax Ratio
| -0.146 | -0.146 | -0.153 | -0.153 | -0.486 | -0.486 | -0.167 | -0.167 | -1.221 | -1.221 | -0.975 | -0.975 | -2.573 | -2.573 | -16.509 | -16.509 |
| Income Tax Expense
| 0.146 | 0.146 | 0.146 | 0.146 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -21.61 | -21.61 | -17.757 | -17.757 | -44.026 | -44.026 | -12.752 | -12.752 | -64.986 | -64.986 | -34.859 | -34.859 | -32.834 | -32.834 | -17.4 | -17.4 |
| Net Income Ratio
| -0.145 | -0.145 | -0.154 | -0.154 | -0.486 | -0.486 | -0.167 | -0.167 | -1.221 | -1.221 | -0.975 | -0.975 | -2.573 | -2.573 | -16.509 | -16.509 |
| EPS
| -0.066 | -0.066 | -0.054 | -0.054 | -0.13 | -0.13 | -0.039 | -0.039 | -0.2 | -0.2 | -0.13 | -0.13 | -0.16 | -0.16 | -0.095 | -0.095 |
| EPS Diluted
| -0.066 | -0.066 | -0.054 | -0.054 | -0.13 | -0.13 | -0.039 | -0.039 | -0.2 | -0.2 | -0.13 | -0.13 | -0.16 | -0.16 | -0.095 | -0.095 |
| EBITDA
| -24.443 | -24.443 | -34.581 | -34.581 | -67.253 | -67.253 | -34.485 | -34.485 | -68.183 | -68.183 | -36.06 | -36.06 | -29.512 | -29.512 | -15.85 | -15.85 |
| EBITDA Ratio
| -0.164 | -0.164 | -0.301 | -0.301 | -0.742 | -0.742 | -0.452 | -0.452 | -1.281 | -1.281 | -1.009 | -1.009 | -2.313 | -2.313 | -15.038 | -15.038 |